Вход на сайт
Просмотр новости

Найдите то, что Вас интересует

FDA approves zanidatamab-hrii and tislelizumab-jsgr for HER2-positive gastric, gastro-oesophageal junction, or oesophageal adenocarcinoma
Дата публикации: 14-10-2026 07:00:00

FDA also approved two companion diagnostic devices

Основное содержимое страницы с новостью.

Subscribe to ESMO newsletter

Login to your ESMO Account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits.

ESMO is a Swiss-registered not-for-profit organisation. All funding for this site is provided directly by ESMO. Via Ginevra 4, 6900 Lugano - CH

© Copyright 2026 European Society for Medical Oncology All rights reserved worldwide.

Схожие новости

#Наименование новостиТональностьИнформативностьДата публикации
1FDA Approves Sacituzumab Govitecan-hziy as Monotherapy and in Combination with Pembrolizumab for First-Line Treatment of TNBC013.9905-08-2026
2FDA Approves Palbociclib with Trastuzumab, With or Without Pertuzumab, and Endocrine Therapy for the Maintenance Treatment of HR-positive, HER2-positive LA/MBC013.1329-07-2026
3FDA Approves Daraxonrasib for Metastatic Pancreatic Adenocarcinoma013.7819-10-2026
4FDA approves Jideytro for previously treated ROS1-positive NSCLC015.4123-07-2026
5FDA Approves Jideytro (zidesamtinib) for Previously Treated ROS1-Positive Non-Small Cell Lung Cancer016.5422-07-2026
6STAT+: FDA approves Bristol multiple myeloma treatment, marking debut of novel drug class04.2314-08-2026
7U.S. Food and Drug Administration Accepts New Drug Application for Zipalertinib for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations011.6828-04-2026
8Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer023.0722-07-2026
9Tumore al pancreas: primo sì dell'Europa al farmaco che raddoppia la sopravvivenza06.1717-10-2026
10U.S. FDA Approves Trodelvy for First-Line Treatment of Metastatic Triple-Negative Breast Cancer020.6624-06-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 30. Источник: www.esmo.org.